Visit our Filed page for categories. To browse by specific topic, see our Inside page. For a list of companies covered on this site, visit our Companies page.
The Food and Drug Administration should better explain its reasons whenever it requires additional safeguards for risky drugs, a pharmaceutical industry group said Monday.
That recommendation is one of dozens expected this week at a public meeting on the FDA’s risk evaluation and mitigation strategies, or REMS, a set of tools to protect consumers from drugs with potentially serious side effects. Get the full story »
Pharmaceutical Research and Manufacturers of America, which includes Abbott Laboratories and Takeda Pharmaceuticals as members, said Tuesday that John Castellani will become the drug lobby’s president and chief executive, effective Sept. 1.
Castellani, who replaces the retiring Billy Tauzin, comes to PhRMA after nearly a decade as president and CEO of Business Roundtable, an association of corporate executives. Get the full story »
